Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients.
CYLD
NF-κβ
Probiotics
Rectal cancer
TNF-α
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
19 Sep 2023
19 Sep 2023
Historique:
received:
21
05
2023
accepted:
12
08
2023
medline:
21
9
2023
pubmed:
19
9
2023
entrez:
19
9
2023
Statut:
epublish
Résumé
The CYLD gene is a tumor suppressor, reduced in many cancers. Here, we aimed to investigate CYLD protein level and NF-κβ/TNF-α signaling pathway in rectal cancer patients with Lactobacillus acidophilus (L. acidophilus) consumption. One hundred ten patients with non-metastatic rectal cancer were randomly divided into L. acidophilus probiotic (500 mg, three times daily) and placebo groups for 13 weeks. The expression of CYLD, TNF-α, and NF-κB proteins and the genes involved in the NF-κβ/TNF-α pathway were evaluated using ELISA and qPCR techniques. The survival rate was measured after five years. Unlike the placebo group, the results showed a significant increase in the expression of CYLD protein and tumor suppressor genes, including FOXP3, ROR-γ, Caspase3, GATA3, T-bet, and a considerable decrease in the expression of NF-ҝβ and TNF-α proteins and oncogenes, including STAT3, 4, 5, 6, and SMAD 3, in the probiotic group. A higher overall survival rate was seen after L. acidophilus consumption compared to the placebo group (P < 0.05). L. acidophilus consumption can reduce inflammation factors by affecting CYLD protein and its downstream signaling pathways. A schematic plot of probiotic consumption Effects on the CYLD protein in regulating the NF-ĸβ signaling pathway in colorectal cancer. NF-ĸβ can be activated by canonical and noncanonical pathways, which rely on IκB degradation and p100 processing, respectively. In the canonical NF-κβ pathway, dimmers, such as p65/p50, are maintained in the cytoplasm by interacting with an IκBα protein. The binding of a ligand to a cell-surface receptor activates TRAF2, which triggers an IKK complex, containing -α, -β, -g, which phosphorylates IKK-β. It then phosphorylates IκB-α, leading to K48-ubiquitination and degradation of this protein. The p65/p50 protein freely enters the nucleus to turn on target genes. The non-canonical pathway is primarily involved in p100/RelB activation. It differs from the classical pathway in that only certain receptor signals activate this pathway. It proceeds through an IKK complex that contains two IKK-α subunits but not NEMO. Several materials including peptidoglycan, phorbol, myristate, acetate, and gram-positive bacteria such as probiotics inhibit NF-κB by inducing CYLD. This protein can block the canonical and noncanonical NF-κβ pathways by removing Lys-63 ubiquitinated chains from activated TRAFs, RIP, NEMO, and IKK (α, β, and γ). Moreover, TNF-α induces apoptosis by binding caspase-3 to FADD.
Identifiants
pubmed: 37725175
doi: 10.1007/s12032-023-02170-y
pii: 10.1007/s12032-023-02170-y
doi:
Substances chimiques
Tumor Necrosis Factor-alpha
0
Deubiquitinating Enzyme CYLD
EC 3.4.19.12
NF-kappa B
0
CYLD protein, human
EC 3.4.19.12
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
302Subventions
Organisme : Iran University of Medical Sciences
ID : 36001
Organisme : Tehran University of Medical Sciences
ID : 29811
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Sivamaruthi BS, Kesika P, Chaiyasut C. The role of probiotics in colorectal cancer management. Evid-Based Complement Altern Med. 2020. https://doi.org/10.1155/2020/3535982 .
doi: 10.1155/2020/3535982
Molska M, Reguła J. Potential mechanisms of probiotics action in the prevention and treatment of colorectal cancer. Nutrients. 2019;11(10):2453.
doi: 10.3390/nu11102453
pubmed: 31615096
pmcid: 6835638
Daniluk U. Probiotics, the new approach for cancer prevention and/or potentialization of anti-cancer treatment. J Clin Exp Oncol. 2012;1:2.
doi: 10.4172/2324-9110.1000e105
Wollowski I, Rechkemmer G, Pool-Zobel BL. Protective role of probiotics and prebiotics in colon cancer. Am J Clin Nutr. 2001;73(2):451s-s455.
doi: 10.1093/ajcn/73.2.451s
pubmed: 11157356
Lei H, et al. Deubiquitinases in hematological malignancies. Biomarker Research. 2021;9(1):1–23.
doi: 10.1186/s40364-021-00320-w
Terzić J, et al. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101-2114.e5.
doi: 10.1053/j.gastro.2010.01.058
pubmed: 20420949
Jono H, et al. NF-κB is essential for induction of CYLD, the negative regulator of NF-κB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem. 2004;279(35):36171–4.
doi: 10.1074/jbc.M406638200
pubmed: 15226292
Pikarsky E, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431(7007):461–6.
doi: 10.1038/nature02924
pubmed: 15329734
Liang H-L, et al. MiR-454 prompts cell proliferation of human colorectal cancer cells by repressing CYLD expression. Asian Pac J Cancer Prev. 2015;16(6):2397–402.
doi: 10.7314/APJCP.2015.16.6.2397
pubmed: 25824771
Sun S. CYLD: a tumor suppressor deubiquitinase regulating NF-κB activation and diverse biological processes. Cell Death Differ. 2010;17(1):25–34.
doi: 10.1038/cdd.2009.43
pubmed: 19373246
Khodaii Z, et al. Novel targets in rectal cancer by considering lncRNA–miRNA–mRNA network in response to Lactobacillus acidophilus consumption: a randomized clinical trial. Sci Rep. 2022;12(1):1–8.
doi: 10.1038/s41598-022-13297-9
Mego M, et al. Probiotic bacteria in cancer patients undergoing chemotherapy and radiation therapy. Complement Ther Med. 2013;21(6):712–23.
doi: 10.1016/j.ctim.2013.08.018
pubmed: 24280481
Rondanelli M, et al. Using probiotics in clinical practice: where are we now? A review of existing meta-analyses. Gut microbes. 2017;8(6):521–43.
doi: 10.1080/19490976.2017.1345414
pubmed: 28640662
pmcid: 5730384
Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr. 2014;33(5):761–7.
doi: 10.1016/j.clnu.2013.10.015
pubmed: 24200199
Flesch AT, et al. Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial. Rev Col Bras Cir. 2017;44:567–73.
doi: 10.1590/0100-69912017006004
pubmed: 29267553
Burns MB, et al. Virulence genes are a signature of the microbiome in the colorectal tumor microenvironment. Genome medicine. 2015;7(1):1–2.
doi: 10.1186/s13073-015-0177-8
Zitvogel L, et al. The microbiome in cancer immunotherapy: diagnostic tools and therapeutic strategies. Science. 2018;359(6382):1366–70.
doi: 10.1126/science.aar6918
pubmed: 29567708
Gianotti L, et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol: WJG. 2010;16(2):167.
doi: 10.3748/wjg.v16.i2.167
pubmed: 20066735
pmcid: 2806554
Karin M, et al. NF-κB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2(4):301–10.
doi: 10.1038/nrc780
pubmed: 12001991
Costello CM, et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2005;2(8): e199.
doi: 10.1371/journal.pmed.0020199
pubmed: 16107186
pmcid: 1188246
Rutter M, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126(2):451–9.
doi: 10.1053/j.gastro.2003.11.010
pubmed: 14762782
Trompouki E, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature. 2003;424(6950):793–6.
doi: 10.1038/nature01803
pubmed: 12917689
Bullock M, et al. FOXO
doi: 10.1038/bjc.2013.355
pubmed: 23828518
pmcid: 3721407
Wang W, et al. Overexpressed GATA3 enhances the sensitivity of colorectal cancer cells to oxaliplatin through regulating MiR-29b. Cancer Cell Int. 2020;20(1):1–6.
Dariya B, et al. Targeting STAT proteins via computational analysis in colorectal cancer. Mol Cell Biochem. 2021;476(1):165–74.
doi: 10.1007/s11010-020-03893-6
pubmed: 32840738
Spano J-P, et al. JAK/STAT signalling pathway in colorectal cancer: a new biological target with therapeutic implications. Eur J Cancer. 2006;42(16):2668–70.
doi: 10.1016/j.ejca.2006.07.006
pubmed: 16963263
Koveitypour Z, et al. Signaling pathways involved in colorectal cancer progression. Cell Biosci. 2019;9(1):1–4.
doi: 10.1186/s13578-019-0361-4
Fang T, et al. Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2021;21(1):1–2.
doi: 10.1186/s12876-021-01864-9